Mizuho Sees Buying Opportunity Despite Weakness In Arcutis

 

• Mizuho remains bullish on Arcutis Biotherapeutics Inc 
  ARQT+6.77%+ Free Alerts
  . It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for ARQT. 
• The most important catalyst is the potential approval of roflumilast cream in plaque psoriasis around July 29, 2022, transforming Arcutis from a developmental- to a commercial-stage company. 
• Mizuho believes the three ongoing Phase 3 clinical programs remain underappreciated by investors. 
• The topline data for seborrheic dermatitis is expected in mid-2022. The analyst expects positive data given the similar trial size and patient enrollment number to the highly positive Phase 2 trial. 
• The analyst expects a positive readout from Phase 3 in scalp psoriasis for scalp psoriasis. 
• The likelihood of success of the Phase 3 studies in atopic dermatitis is questionable as Phase 2 missed the EASI primary endpoint. The Phase 2 trial was also underpowered. 

https://www.benzinga.com/analyst-ratings/analyst-color/22/05/27424638/mizuho-sees-buying-opportunity-despite-weakness-in-this-skin-disease-focused-stock